[an error occurred while processing this directive] ����Ƥ���Բ�ѧ��־ 2008, 34(5) 330-332 DOI:     ISSN: 2096-5540 CN: 32-1880/R

����Ŀ¼ | ����Ŀ¼ | ������� | �߼�����                                                            [��ӡ��ҳ]   [�ر�]
����
��չ����
������Ϣ
Supporting info
PDFȫ��
[HTMLȫ��]
�����
�����뷴��
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
����
Email Alert
���·���
���������Ϣ
���Ĺؼ����������
��ϸ������12������������
���������������
������
��ѧ˼
��ǧ��
PubMed
Article by
Article by
Article by

�׽���12���������õĽ�չ

������ ��ѧ˼ ��ǧ��

�Ϻ���Ƥ�����Բ�ҽԺ �Ͼ�ҽ��ԺƤ���� �Ͼ�ҽ��ԺƤ����

ժҪ��

�׽���12�ǿ�����ϸ�����ӣ���Ҫ�ɵ���ϸ������ͻϸ���;���ϸ�����ڡ�����Ҫ����������Ϊ���ٽ��������ߺͻ�������ߡ������������Ѫ�����ɡ��ӳ�����ǿ���߼��䡣Ƥ�»������ڸ���׽���12�ĵ���Ӧ�ü������ԵĿ��������ã������������Ƽ������俹����Ч����ǿ���׽���12���ƵIJ�����Ӧ��Ҫ������ע��ֲ�����֢��Ӧ�Լ�ȫ��Ӧ���ڿ��������������У��׽���12��������ֵ�ý�һ���о���

�ؼ����� ��ϸ������12������������  

Anti-tumor effect of interleukin-12

Abstract:

Interleukin 12 (IL-12) is an important anti-tumor cytokine mainly secreted by monocytes, dendritic cells and macrophages. The anti-tumor mechanisms of IL-12 mainly involve augmenting innate and adaptive immunity, indirectly inhibiting angiogenesis within the tumors, prolonging the period and enhancing the extent of immune memory. Subcutaneous or introtumorous application of IL-12 alone shows obvious anti-tumor effect, which can be enhanced by the combination with other immune agents. The adverse events of IL-12 mainly include local inflammatory reactions caused by injection and systemic reactions. In conclusion, further studies are needed on the application of IL-12 as a vaccine adjuvant in anti-tumor therapy.

Keywords: interleukin 12��anti-tumor immunity  
�ո����� 2007-11-22 �޻����� 2008-05-10 ����淢������  
DOI:
������Ŀ:

ͨѶ����: ������
���߼��:

�ο����ף�
�������������

�������� (��ע��:��վʵ�������Ը�, �벻Ҫ������ѧ���޹ص�����!�������ݲ�����վ�۵�.)

Copyright 2008 by ����Ƥ���Բ�ѧ��־